Trial Profile
A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1306 Tablet in Patients With Primary Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2019
Price :
$35
*
At a glance
- Drugs Ezetimibe/rosuvastatin (Primary) ; HGP 0816
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms MRS-ROZE
- Sponsors Hanmi Pharmaceutical
- 11 Nov 2019 Results (n=407) of post-hoc analysis assessing combination treatment with ezetimibe and rosuvastatin in patients with hupercholesterolemia, published in the Clinical Therapeutics.
- 21 Sep 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 05 Aug 2014 New trial record